Pharming Group N.V. is a biopharmaceutical company that develops and sells protein replacement therapies and precision medicines to treat rare diseases and medical needs worldwide. The company's lead product, Ruconest, is used to treat acute hereditary angioedema, and it also develops treatments for various other ailments such as COVID-19. Pharming Group N.V. collaborates with Novartis and Orchard Therapeutics to develop gene therapies for the treatment of hereditary angioedema.